Increasing use of disease modifying drugs for MS in Canada

Canadian Journal of Neurological Sciences

Volumn 37, Issue 3, 2010, Pages 383-388

  Rotstein, Dalia L ^a   Mamdani, Muhammad ^a   O'Connor, Paul W ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ARTICLE; CANADA; COHORT ANALYSIS; DRUG COST; DRUG USE; MULTIPLE SCLEROSIS; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 77950683809     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100010295     Document Type: Article

References (20)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. NEJM. 2000;343:938-952
2. Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, et al. Comparison of subcutaneous interfereon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (REGARD study): a mulicentre, randomised, parallel, openlabel trial. Lancet Neurol. 2008;7:903-914
3. Goodin DS, Cohen BA, O'Connor P. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;71:766-773
4. O'Connor P, Devonshire V, Canadian Network of MS Clinics. The use of disease-modifying agents in multiple sclerosis - by the Canadian network of MS clinics. Can J Neurol Sci. 2008;35: 127-132
5. Beck CA, Metz LM, Svenson LW, Patten SB. Regional variation of multiple sclerosis prevalence in Canada. Mult Scler. 2005;11: 516-519 (Pubitemid 41387694)
6. Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in the United Sates and evidence of an increasing trend for women. Neurology. 2002;58:136-138
7. Berg J, Lindgren P, Fredrikson S, Kobelt G. Costs and quality of life of multiple sclerosis in Sweden. Eur J Health Econ. 2006;Suppl 2:S75-85. (Pubitemid 46318948)
8. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66:1696-1702 (Pubitemid 43964625)
9. Imshealthcanada.com [homepage on the Internet]. Toronto: IMS Health Incorporated; c2009 [cited 2009 Oct 12]. Available from: http://www. imshealthcanada.com/.
10. Statcan.gc.ca[homepage on the Internet]. Ottawa: Statistics Canada; c2006 [updated 2008 Aug 21; cited 2008 Nov 13]. Available from: http://www12.statcan. ca/english/census06/.
11. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. NEJM. 2000;343(13):898-904.
12. Kinkel RP, Kollman C, O'Connor P, Murray TJ, Simon J, Arnold D, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology. 2006;66(5): 678-684 (Pubitemid 43739821)
13. Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis. Report of the Therapy and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. February 2002.
14. Canadian Institute of Health Information. National survey of selected medical imaging equipment; 2003-2007.
15. The European Study Group on interferon beta-1b in secondary progressive MS. Placebo controlled multicentre randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;352(9139):1491-1497
16. Panitch H, Miller A, Paty D,Weinshenker B. North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004;63(10):1788-1795 (Pubitemid 39532370)
17. Hauser SL, Johnston SC. Scripts for science: a new wrinkle on academic ties with industry. Ann Neurol. 2008;64(4):A13-5.
18. Warren SA, Svenson LW, Warren KG. Contribution of incidence to increasing prevalence of MS in Alberta, Canada. Mult Scler. 2008;14:872-879
19. Jackevicius CA, Tu JV, Ross JS, Ko DT, Krumholz HM. Use of ezetimibe in the United States and Canada. NEJM. 2008;358: 1819-1828 (Pubitemid 351581194)
20. Tu JV, Pashos CL, Naylor CD, Chen E, Normand S-L, Newhouse JP, et al. Use of cardiac procedures and outcomes in elderly patients with myocardial infarction in the United States and Canada. NEJM. 1997;336(21):1500-1505